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Three pathways of complement activation. 
Deposition of clusters of C3b on a target is 
the primary goal. The alternative pathway also 
serves as a feedback loop such that C3b depo-
sition can be amplified (shown by broken line).
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Evolution of the complement system
The complement system is an ancient host 
defense  pathway. As  organisms  became 
complex,  the system evolved to be more 










































Lectin pathway. This pathway, also called the 
MBL pathway, is activated by the binding of 
MBL and other lectins to sugar moieties on the 
surface of pathogens, which results in cleav-
age of C4 and C2 to produce the C3 conver-
tase C4b2a. The convertase that is formed is 
the same as that in the classical pathway of 
complement activation.
Figure 3
Feedback loop of the alternative pathway. C3b is formed by spontaneous C3 turnover in blood or generated by the lectin or classical pathways. 
C3b bound to a substrate binds the serine protease factor B (B). This low-affinity complex is converted by the serine protease factor D (D) to a 
C3-cleaving enzyme, C3bBb. This enzyme complex is stabilized by properdin (P). C3bBbP then cleaves C3 to C3a and C3b to complete the 
loop and lead to amplification.
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recognize. An obvious approach to uncover 
these earlier renditions of the complement 
























































































































Lectin pathway in normal versus C2-deficient serum. In this issue of the JCI, Selander 
et al. (7) examined the mechanism of complement activation by MBL in the setting of C2 
deficiency. Lectins bind sugar moieties on target pathogens and subsequently activate 
complement via MASPs. In normal human sera, MASPs cleave C4 and C2 to form the 
C3 convertase C4b2a. Surprisingly, Selander et al. found that in human sera from indi-
viduals deficient in C4 or C2, MBL is still capable of inducing substantial C3 deposition 
by engagement of the alternative pathway and formation of the C3 convertase C3bBb. 
This bypass pathway may be functioning in individuals with acquired or naturally occur-
ring complement deficiencies.
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mediated by complement bypass systems. 
Fourth, and probably most important, the 
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The IL-23/IL-17 axis in inflammation
Yoichiro Iwakura and Harumichi Ishigame










Th17/ThIL-17 is a new CD4+ helper  



































IL-6,  TNF-α ,   NOS-2,  metalloprote-
ases,  and  chemokines,  resulting  in  the 
induction of  inflammation  (5, 6).  IL-17 
expression  is  increased  in patients with 
a  variety  of  allergic  and  autoimmune 
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